December 16, 2016
Continued treatments with the prostate cancer drug Xtandi (enzalutamide) on top of Zytiga (abiraterone acetate) plus prednisone in chemotherapy-naïve advanced prostate cancer patients failed to extend progression-free survival (PFS), according to post-marketing trial data. In the PLATO study conducted in...read more